Interesting discussion. I would hope the other IPs for the other indications add a bit of cream to the mix.
For DMD, it has been found that fixing dystrophin along isnt very beneficial. In fact no treatment has yet equalled the previous ATL1102 trial. So the treatment of inflammation looks like it may be the required pathway.
I would hope, this, the platform drug potential and enough cash to get to some results would put the company in a better bargaining position, if discussion was to take place.
Hopefully our ex CSL folk add a bit of savvy.
Viralytics had their cancer drug bought for $aud500 million, before the drug was shelved. So thats about 9 bags from where we are now. Would the platform potential add extra value?
For General Information, page-2871
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.001(1.25%) |
Mkt cap ! $83.73M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.2¢ | 7.9¢ | $153.8K | 1.914M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 927041 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 218878 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |